Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
批准号:
10818834
负责人:
RENATO V. IOZZO
金额:
$6.18万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-01 至 2025-06-30
关键词:
AMP-activated protein kinase kinaseAffectAffinityAllograftingAngiogenesis InhibitorsAngiogenic FactorAngiostatic ProteinsAutophagocytosisBindingBiologicalBiologyBreast Cancer cell lineBreast CarcinomaC-terminalCancer BiologyCellsCellular StressChemicalsCommunicationComplexCore ProteinCuesDevelopmentDiseaseEatingEndothelial CellsEndotheliumEnzymesExonsFemaleFibroblast Growth Factor ReceptorsFundingGADD45A geneGene TargetingGeneticGenetic TranscriptionGrantGrowthHAS2 geneHeparan Sulfate ProteoglycanHyaluronanImmunologicsIn VitroIntegrinsKDR geneKnowledgeLaboratoriesLigationLinkMalignant NeoplasmsMediatingMethodologyModalityModelingMolecularMusMutateNamesNeoplasm MetastasisNutrientOxygenPTPN6 geneParentsParkinPathway interactionsPhosphoric Monoester HydrolasesPhosphorylationPhosphorylation SitePhosphotransferasesProtein Tyrosine PhosphataseProteinsProteoglycanRecombinantsRegulationResearchRoleSecond Primary CancersSensitivity and SpecificitySignal TransductionSpecificityStromal CellsTamoxifenTechnologyTestingTimeTransgenic MiceTranslatingTumor AngiogenesisVEGFA geneVascular EndotheliumVascularizationWorkZebrafishadhesion receptoraggressive breast cancerangiogenesisantagonistattenuationcancer cellcell behaviorcellular engineeringclinically relevantcombatconfocal imagingexperimental studygenetic signaturein vivoinducible Creinhibitorinnovationinterdisciplinary approachmTOR InhibitormTOR inhibitionmalignant breast neoplasmmortalitymouse modelmutantnano-stringneoplastic cellneovascularizationnovelnovel therapeuticsnutrient deprivationoverexpressionparacrineperlecanpredict clinical outcomeprogramspromoterreceptorsensortranscriptometranscriptomicstumortumor microenvironmenttumor progressiontumorigenesistumorigenicultra high resolution
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Chief among female mortality is the development, progression, and metastasis of aggressive breast cancer. The
bidirectional communication between the neoplastic cells and the tumor microenvironment, which supplies
oxygen and nutrients, is essential for promoting unchecked tumorigenic development, aberrant
neovascularization, and widespread metastasis. Thus, a better understanding of embedded cues and soluble
messages exchanged between these two compartments will prove invaluable for furthering our knowledge of
the pathobiology of cancer and for reliably predicting clinical outcomes.
Our central hypothesis is that endorepellin, a proteolytic fragment of perlecan, a multi-domain heparan sulfate
proteoglycan, exploits a dual-receptor antagonism to preclude endothelial cells from participating in tumor
angiogenesis. This working hypothesis is based on an impactful and promising body of work all generated under
the auspices of this grant. We discovered that: [a] Endorepellin simultaneously ligates, with high affinity,
VEGFR2 and the 2
Engagement of both receptors underscores the exquisite sensitivity and specificity of endorepellin in targeting
the endothelia. [b] Endorepellin triggers co-internalization of VEGFR2 and 2 1 integrin with concurrent
activation of the SHP-1 tyrosine phosphatase and attenuation of VEGFA signaling. [c] Endorepellin induces
endothelial cell autophagy in a Peg3-dependent manner by modulating Beclin 1, LC3, and p62 expression,
processing, and cellular localization. [d] Endorepellin evokes protracted activation of the energy-sensor kinase
AMPK , irrespective of energy levels. Indeed, this regulation is considered non-canonical as AMPK
phosphorylation occurred under nutrient-enriched conditions. [e] Downstream of AMPK , endorepellin evokes
autophagic flux in endothelial cells that mechanistically parallels the mTOR inhibitor, Torin 1. These striking
findings demonstrate that protracted and sustained autophagy is a novel mechanism by which endorepellin
promotes angiostasis, independent of nutrient deprivation. Based on these discoveries, we plan to:
[1] Elucidate the mechanism of endorepellin-evoked endothelial cell stress, autophagy and mitophagy.
[2] Unravel the mechanism by which endorepellin induces autophagic suppression of HAS2.
[3] Generate novel mouse models of tumorigenesis to explain the pro-autophagic and anti-angiogenic programs
activated by endorepellin.
These concerted research aims will enable us to translate our findings, procured with highly innovative mouse
models of stromal autophagy, into clinically relevant paradigms. The discovery of endorepellin-induced
endothelial cell autophagy downstream of dual receptor antagonism will lead to new therapeutic advances that
actively induce autophagy within the tumor microenvironment to combat this devastating disease.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
-
批准号:10186719
-
项目类别:
-
资助金额:$38.56万
-
财政年份:2020
-
负责人:RENATO V. IOZZO
-
依托单位:
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
-
批准号:10634656
-
项目类别:
-
资助金额:$37.79万
-
财政年份:2020
-
负责人:RENATO V. IOZZO
-
依托单位:
Proteoglycan regulation of tumor angiogenesis and endothelial cell autophagy
-
批准号:10439783
-
项目类别:
-
资助金额:$37.79万
-
财政年份:2020
-
负责人:RENATO V. IOZZO
-
依托单位:
Progranulin signaling in bladder cancer
-
批准号:8686782
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2012
-
负责人:RENATO V. IOZZO
-
依托单位:
Progranulin signaling in bladder cancer
-
批准号:8521204
-
项目类别:
-
资助金额:$30.23万
-
财政年份:2012
-
负责人:RENATO V. IOZZO
-
依托单位:
Progranulin signaling in bladder cancer
-
批准号:9095251
-
项目类别:
-
资助金额:$32.16万
-
财政年份:2012
-
负责人:RENATO V. IOZZO
-
依托单位:
Altered Proteoglycan Gene Expression and Cancer
-
批准号:7909761
-
项目类别:
-
资助金额:$14.51万
-
财政年份:2009
-
负责人:RENATO V. IOZZO
-
依托单位:
Natural EGFR Antagonists and Cancer
-
批准号:7314465
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2007
-
负责人:RENATO V. IOZZO
-
依托单位:
Natural EGFR Antagonists and Cancer
-
批准号:7472307
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2007
-
负责人:RENATO V. IOZZO
-
依托单位:
Natural EGFR Antagonists and Cancer
-
批准号:7646319
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2007
-
负责人:RENATO V. IOZZO
-
依托单位:
Natural EGFR Antagonists and Cancer
-
批准号:7888338
-
项目类别:
-
资助金额:$23.56万
-
财政年份:2007
-
负责人:RENATO V. IOZZO
-
依托单位:
GORDON RESEARCH CONFERENCE ON PROTEOGLYCANS
-
批准号:6085272
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2000
-
负责人:RENATO V. IOZZO
-
依托单位:
HEPARAN SULFATE AND TRANSFORMATION
-
批准号:3190821
-
项目类别:
-
资助金额:$16.58万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
Biology of Perlecan in Cancer
-
批准号:6383808
-
项目类别:
-
资助金额:$32.7万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
BIOLOGY OF PERLECAN IN CANCER AND DEVELOPMENT
-
批准号:2882354
-
项目类别:
-
资助金额:$29.23万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
Biology of Perlecan in Cancer
-
批准号:7277496
-
项目类别:
-
资助金额:$6.46万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
The Biology of Perlecan in Cancer and Angiogenesis
-
批准号:8503101
-
项目类别:
-
资助金额:$35.62万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
The Biology of Perlecan in Cancer and Angiogenesis
-
批准号:8101073
-
项目类别:
-
资助金额:$35.51万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
HEPARAN SULFATE AND TRANSFORMATION
-
批准号:3190820
-
项目类别:
-
资助金额:$15.39万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
BIOLOGY OF PERLECAN IN CANCER AND DEVELOPMENT
-
批准号:2667910
-
项目类别:
-
资助金额:$27.84万
-
财政年份:1990
-
负责人:RENATO V. IOZZO
-
依托单位:
海外基金